ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with ⁸⁹Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.

ABSTRACT:

Background

ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if ⁸⁹Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials.

Methods

The phase 0 study recruited 5 PD-L1+ patients with metastatic non-small cell lung cancer (NSCLC). Patients received 60MBq/70 kg ⁸⁹Zr-durva up to a maximum of 74 MBq, with scan acquisition at days 0, 1, 3 or 5±1 day. Data on (1) Percentage of injected ⁸⁹Zr-durva dose found in organs of interest (2) Absorbed organ doses (µSv/MBq of administered ⁸⁹Zr-durva) and (3) whole-body dose expressed as mSv/100MBq of administered dose was collected to characterise biodistribution.The phase 1 study will recruit 20 patients undergoing

SUBMITTER: Hegi-Johnson F 

PROVIDER: S-EPMC9677006 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature